Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Endocrinol Metab ; 96(9): 2675-80, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21752890

RESUMEN

CONTEXT: Atypical femoral fractures have rarely been reported in women taking bisphosphonates, but this is still a controversial issue. Data are derived mainly from observation studies because a post hoc analysis from a randomized clinical trial did not find any such association. OBJECTIVE: The aim of this study was to report three cases of what are considered atypical femoral fractures and their responses to the use of strontium ranelate and teriparatide. PATIENTS: We studied three postmenopausal women with a diagnosis of osteoporosis who suffered fractures of the subtrochanteric region and femoral diaphysis with no major trauma while on long-term use of bisphosphonates. RESULTS: All the major features of atypical femoral fractures highlighted in the Task Force Report of the American Society for Bone and Mineral Research were present in the three cases. They had had unconsolidated fractures for approximately 1 yr before being referred to our center. After 3 months on strontium ranelate 2 g/d, serum osteocalcin and serum ß-carboxyterminal telopeptide had increased in case 1 by 125 and 100%, respectively, and in case 2 by 50 and 22%, respectively, with total closure of the fracture. In case 3, after 1 month on teriparatide 20 µg/d, a radiographic closure of the fracture was achieved, and 3 months later serum osteocalcin and serum ß-carboxyterminal telopeptide had increased by 300 and 22%, respectively. CONCLUSION: Our finding showed that both teriparatide and strontium ranelate had a rapid bone anabolic effect on unhealed atypical fractures associated with chronic bisphosphonate use.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Difosfonatos/uso terapéutico , Fracturas del Fémur/etiología , Compuestos Organometálicos/uso terapéutico , Osteoporosis/tratamiento farmacológico , Teriparatido/uso terapéutico , Tiofenos/uso terapéutico , Anciano , Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/efectos adversos , Femenino , Humanos , Persona de Mediana Edad
2.
J Am Acad Orthop Surg ; 6(6): 349-57, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9826418

RESUMEN

In athletes, the rarely identified malady of osteoporosis differs from other chronic effects of exercise. The most obvious difference is that hormonal imbalance leads to compensatory mechanisms that in turn lead to osteoporosis and increased incidence of fracture. Most research on this subject has dealt with women, because hormonal imbalances in women are easier to detect than those in men. Endurance athletes are known to have decreased levels of sex hormones, which can cause physiologic changes that lead to bone loss. This may result in relative osteoporosis despite the loading of the bone during exercise, which would normally increase bone mineral density. Premature osteoporosis may be irreversible, causing young athletes to become osteoporotic at an earlier age and have an increased risk of fracture later in life.


Asunto(s)
Densidad Ósea , Ejercicio Físico , Osteoporosis/etiología , Deportes , Adolescente , Adulto , Remodelación Ósea/fisiología , Calcio de la Dieta/administración & dosificación , Femenino , Hormonas Esteroides Gonadales/deficiencia , Humanos , Masculino , Persona de Mediana Edad , Necesidades Nutricionales , Osteoporosis/diagnóstico , Osteoporosis/terapia , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...